Circulating intranuclear proteins may play a role in development of disseminated intravascular coagulation in individuals with acute leukemia

2019 ◽  
Vol 111 (3) ◽  
pp. 378-387 ◽  
Author(s):  
Kayo Harada-Shirado ◽  
Xintao Wang ◽  
Hirotaka Mori ◽  
Masahiko Fukatsu ◽  
Hiroshi Takahashi ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Disseminated Intravascular Coagulation ◽  
Intravascular Coagulation

Disseminated Intravascular Coagulation in Acute Leukemia at Presentation and During Induction Therapy

2007 ◽  
Vol 13 (3) ◽  
pp. 292-298 ◽  
Author(s):  
Ashish Dixit ◽  
Tathagat Chatterjee ◽  
Pravas Mishra ◽  
Meganathan Kannan ◽  
Dharma R. Choudhry ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Induction Therapy ◽  
Disseminated Intravascular Coagulation ◽  
Intravascular Coagulation

Disseminated intravascular coagulation in acute leukemia: clinical and laboratory features at presentation

2006 ◽  
Vol 77 (4) ◽  
pp. 282-287 ◽  
Author(s):  
Masamitsu Yanada ◽  
Tadashi Matsushita ◽  
Momoko Suzuki ◽  
Hitoshi Kiyoi ◽  
Koji Yamamoto ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Disseminated Intravascular Coagulation ◽  
Intravascular Coagulation ◽  
Laboratory Features

scholarly journals Clinical Features of Disseminated Intravascular Coagulation According to the French-American-British Classification in Patients With Acute Leukemia and Thrombomodulin Alfa Treatment—A Cohort Study Using a Postmarketing Surveillance Database

2021 ◽  
Vol 27 ◽  
pp. 107602962110540
Author(s):  
Seki Yoshinobu ◽  
Goichi Honda ◽  
Noriaki Kawano ◽  
Toshimasa Uchiyama ◽  
Kazuo Kawasugi ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Clinical Features ◽  
Disseminated Intravascular Coagulation ◽  
Lymphoblastic Leukemia ◽  
Postmarketing Surveillance ◽  
Intravascular Coagulation ◽  
Plasmin Inhibitor ◽  
Surveillance Database ◽  
French American British

The aims of this study were to analyze the clinical features of a large number of cases with disseminated intravascular coagulation (DIC) associated with acute leukemia and to assess the safety and efficacy of thrombomodulin alfa (TM-α) using the French-American-British (FAB) classification of hematological malignancies. We retrospectively examined 644 patients with acute leukemia in postmarketing surveillance for TM-α. M3, M2, M4, M1, and M5 subtypes of acute myeloid leukemia (AML) and L2 and L1 subtypes of acute lymphoblastic leukemia (ALL) have been found more frequently among patients with DIC. Bleeding symptoms at baseline were more frequent in M3 and M7 subtypes. Fibrinogen concentrations were lower, and plasmin-plasmin inhibitor complex values were higher in M3 and Philadelphia-positive (Ph+) ALL. Overall DIC resolution rate was 60.2%, higher in L1 and Ph+ ALL, lower in M1, and generally higher in ALL than in AML. Overall survival rate was generally high, at 79.8%, with higher rates in L3, Ph+ ALL, and M3. Regardless of FAB subgroup, TM-α showed improved bleeding symptoms and DIC scores in clinical practice for DIC patients with acute leukemia.

Sign in / Sign up

Export Citation Format

Share Document